Print the page
Increase font size

Posted February 09, 2021

Ray Blanco

By Ray Blanco

Google vs. Death

Back in 2013, Google launched a biotech venture, Calico, with a lofty goal in mind -- to defeat aging.

News outlets were quickly buzzing about the huge potential this little biotech company had.

But since then, progress has been slow-going Calico struck a multibillion-dollar deal with pharmaceutical giant AbbVie in 2014, which was later renewed in 2018.

Together the pair just started the first clinical trials for a cancer drug in October 2020.

But after a little over seven years, it seems like this breakthrough company doesnt have much to show for it.

Digging a little deeper, however, tells a more exciting story.

Lets start first with some news from December

Cognitive Improvement in Just Days

In a new study published Dec. 1, 2020, researchers administered a drug called ISRIB to aged mice. ISRIB works by rebooting cells' protein production machinery.

Within days, they observed rapid restoration of youthful cognitive abilities.

Data from the trial suggested that:

The aged brain has not permanently lost essential cognitive capacities, as was commonly assumed, but rather that these cognitive resources are still there but have been somehow blocked, trapped by a vicious cycle of cellular stress. [The] work with ISRIB demonstrates a way to break that cycle and restore cognitive abilities that had become walled off over time.

And the license to this age-defying drug is held by none other than Calico.

Of course, these studies are being done on mice, so its too early to tell if this holds any promise for human aging.

But scientists are already speculating what this could mean for the field

Uses in Fighting Alzehimers

In further experiments with ISRIB researchers tested the drug on mice with fully developed Alzheimers-like symptoms, mimicking the disease at its more advanced stages.

They found that ISRIB could, in fact, work to restore cognitive processes impaired by Alzheimers disease.

Alzheimers is a complicated disease, which means fighting it is a difficult task for any biotech to take on.

Which is also probably why Calico tends to keep the news of ISRIBs successes on the down-low.

But even if on the surface it seems like this company hasnt made any progress in the aging field, its whats going on behind closed doors that interests us more.

And with Google at its helm, there will be no shortage of funds to further this research in 2021 and beyond.

Sincerely,

Brittan Gibbons-ONeill

The Path to Treating Alzheimer’s

The Path to Treating Alzheimer’s

Posted July 30, 2021

By Ray Blanco

Alzheimer’s is one of the most heartbreaking diseases out there. But we may be closer to a cure than you think…
Three Pro Tips to Keep Your Head Up When Stocks Go Down

Three Pro Tips to Keep Your Head Up When Stocks Go Down

Posted July 29, 2021

By Jonathan Rodriguez

All right, all right! I'm J-Rod and welcome back to Stocks That Rock. Each week, I turn up the volume on a breakout stock that will rock your retirement account. Today, however, we're...

Bitcoin’s Knocking on $40K! (What You Need to Know)

Posted July 28, 2021

By Jonas Elmerraji

Just like that, the Bitcoin breakout’s back in play. But does it have teeth this time?
Artificial Intelligence Is Under Attack…

Artificial Intelligence Is Under Attack…

Posted July 27, 2021

By Ray Blanco

The campaign against Big Tech has been ramping up and this latest piece of legislation against AI is one of the most restrictive yet. Here’s where I believe their thinking is all wrong…
Amazon Accepting Bitcoin?

Amazon Accepting Bitcoin?

Posted July 26, 2021

By Ray Blanco

Despite fears of the new Delta variant, the economy’s booming. And many of these fears like inflation don’t seem to be slowing anything down. All the while, there are some exciting things we’re looking at on the horizon.
Apple, Tesla, Biogen: What I’m Looking for in Next Week’s Earnings…

Apple, Tesla, Biogen: What I’m Looking for in Next Week’s Earnings…

Posted July 23, 2021

By Ray Blanco

Earnings season for the Big Tech companies has kicked off! And what a ride thus far. Plenty of companies have beaten their expected revenue goals. And next week I have my eye on...